A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer.

Trial Profile

A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Fluorouracil; Folinic acid
  • Indications Colon cancer; Rectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 Nov 2017.
    • 22 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
    • 22 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top